257 related articles for article (PubMed ID: 31465283)
1. Are Surgical Rates Decreasing in the Biological Era In IBD?
Candido FD; Fiorino G; Spadaccini M; Danese S; Spinelli A
Curr Drug Targets; 2019; 20(13):1356-1362. PubMed ID: 31465283
[TBL] [Abstract][Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
4. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
[TBL] [Abstract][Full Text] [Related]
5. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
7. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
8. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity.
Niewiadomski O; Studd C; Hair C; Wilson J; Ding NS; Heerasing N; Ting A; McNeill J; Knight R; Santamaria J; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Popp B; Connell W; Desmond P; Bell S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1346-53. PubMed ID: 25867770
[TBL] [Abstract][Full Text] [Related]
9. Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy: A Multicenter Experience from Romania.
Pavel C; Diculescu M; Constantinescu G; Plotogea OM; Sandru V; Meianu C; Dina I; Pop I; Butuc A; Mihaila M; Stan-Ilie M
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837538
[No Abstract] [Full Text] [Related]
10. [Changing paradigm in the management of inflammatory bowel disease].
Jang BI
Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972
[TBL] [Abstract][Full Text] [Related]
11. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
[TBL] [Abstract][Full Text] [Related]
12. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Costa J; Magro F; Caldeira D; Alarcão J; Sousa R; Vaz-Carneiro A
Inflamm Bowel Dis; 2013 Sep; 19(10):2098-110. PubMed ID: 23860567
[TBL] [Abstract][Full Text] [Related]
13. Advances in the surgical management of inflammatory bowel disease.
Nandivada P; Poylin V; Nagle D
Curr Opin Gastroenterol; 2012 Jan; 28(1):47-51. PubMed ID: 22134218
[TBL] [Abstract][Full Text] [Related]
14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
15. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease.
Vohra P
Indian J Pediatr; 2000 Oct; 67(10):747-56. PubMed ID: 11105426
[TBL] [Abstract][Full Text] [Related]
17. Current therapeutic approaches in inflammatory bowel disease.
Sohrabpour AA; Malekzadeh R; Keshavarzian A
Curr Pharm Des; 2010; 16(33):3668-83. PubMed ID: 21128898
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
19. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
D'Haens G; Daperno M
Curr Gastroenterol Rep; 2006 Dec; 8(6):506-12. PubMed ID: 17105690
[TBL] [Abstract][Full Text] [Related]
20. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
